Focus: Rhythm Pharmaceuticals is a public biotech focused on peptide therapeutics for neurology, with a peak-stage product (IMCIVREE/setmelanotide) and emerging pipeline in hypothalamic obesity. The company operates at 201–500 employees and generated $77M revenue in FY2025.
Profile data last refreshed 8h ago · AI intelligence enriched 1w ago
Growing — net +7 jobs in 30d
27 jobs added vs 20 removed. Steady team buildout.
Rhythm offers growth-stage opportunity in a focused peptide franchise, but financial model is pre-profitability and pipeline-thin; best for candidates seeking high R&D intensity with IPO-stage upside and tolerance for restructuring risk.
Help build intelligence for Rhythm Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rhythm Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
FDA-approved melanocortin 4 receptor agonist and company's sole marketed product; 9+ years of exclusivity remaining provides revenue runway but creates single-product risk.
Rhythm Pharmaceuticals Inc. (RYTM) Peer Comparison – Compare with Others - valueresearchonline.com
Rhythm Pharmaceuticals Inc. (RYTM) Peer Comparison – Compare with Others valueresearchonline.com
Rhythm Pharmaceuticals Expands Market Potential with New Drug Approvals - Intellectia AI
Rhythm Pharmaceuticals Expands Market Potential with New Drug Approvals Intellectia AI
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise (NASDAQ:RYTM) Seeking Alpha
JPMorgan initiates Rhythm Pharmaceuticals stock at Overweight - Investing.com
JPMorgan initiates Rhythm Pharmaceuticals stock at Overweight Investing.com
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Yahoo Finance
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 Yahoo Finance
Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data - Investing.com
Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data Investing.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo